Hypersensitivity to aspirin and other NSAIDs: Mechanisms, clinical presentation and management

Drug Hypersensitivity

Volumn , Issue , 2007, Pages 340-349

  Szczeklik, A ^a   Nizankowska Mogilnicka, E ^a   Sanak, M ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70450130414     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000104211     Document Type: Chapter

References (38)

1. Hirschberg VGS: Mittelung über einen Fall von Nebenwirkung des Aspirin Dtsch Med Wochenschr 1902; 28: 416-417 and A case report on the side ef-fects of aspirin. Allergy Proc 1990; 11: 249-250.
2. Widal MF, Abramin P, Lermoyez J: Anaphylaxie et idiosyncrasie. Presse Méd 1922; 30: 189-192.
3. Samter S, Beers RF Jr: Intolerance to aspirin. Clinical studies and consider-ation of its pathogenesis. Ann Intern Med 1968; 68: 975-983.
4. Szczeklik A, Gryglewski RJ, Czerniaw-ska-Mysik G: Relationship of inhibition of prostaglandin biosynthesis by anal-gesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975; 1: 67-69.
5. Kasper L, Sladek K, Duplaga M, et al: Prevalence of asthma with aspirin hy-persensitivity in the adult population of Poland. Allergy 2003; 58: 1064-1066.
6. Gomes E, Cardoso MF, Praca F, Gomes L, Marino E, Demoly P: Self-reported drug allergy in a general adult Portu-guese population. Clin Exp Allergy 2004; 34: 1597-1601.
7. Szczeklik A, Sanak M: The broken bal-ance in aspirin hypersensitivity. Eur J Pharmacol 2006; 533: 145-155.
8. Jenkins C, Costello J, Hodge L: System-atic review of prevalence of aspirin-induced asthma and its implications for clinical practice. BMJ 2004; 328: 434-437.
9. Szczeklik A, Stevenson DD: Aspirin-induced asthma: advances in pathogen-esis diagnosis, and management. J Al-lergy Clin Immunol 2003; 111: 913-921.
10. Debley JS, Carter ER, Gibson RL, Rosenfeld M, Redding GJ: The preva-lence of ibuprofen-sensitive asthma in children: a randomized controlled bronchoprovocations challenge study. J Pediatr 2005; 147: 233-238.
11. Szczeklik A, Nizankowska E, Duplaga M: Natural history of aspirin-induced asthma. AIANE Investigators. Euro-pean Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16: 432-436.
12. Berges-Gimeno M, Simon RA, Steven-son DD: The natural history and clini-cal characteristics of aspirin exacerbat-ed respiratory disease. Ann Allergy Asthma Immunol 2002; 89: 474-478.
13. Szczeklik A: Aspirin-induced asthma as a viral disease. Clin Allergy 1988; 18: 15-20.
14. Koga T, Oshita Y, Kamimura T, Koga H, Aizawa H: Characterisation of patients with frequent exacerbation of asthma. Respir Med 2006; 100: 273-278.
15. Yoshimine F, Hasegawa T, Suzuki E, Terada M, Koya T, Kondoh A, Arakawa M, Yoshizawa H, Gejyo F: Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan Respirology 2005; 10: 477-484.
16. Szczeklik A, Gryglewski RJ, Czerniaw-ska-Mysik G: Clinical patterns of hy-persensitivity to nonsteroidal anti-in-flammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977; 60: 276-284.
17. Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z: Safety of selective COX-2 inhibitors in aspirin/NSAID-intolerant patients: comparison of nimesulide, meloxicam and rofecoxib. J Asthma 2004; 41: 67-75.
18. Baldassarre S, Schandene L, Choufani G, Michils A: Asthma attacks induced by low doses of celecoxib, aspirin and acetaminophen. J Allergy Clin Immu-nol 2006; 117: 215-217.
19. Mastalerz L, Sanak M, Gawlewicz A, Gielicz A, Faber J, Szczeklik A: Differ-ent eicosanoid profile of the hypersen-sitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis and asthma. J Allergy Clin Immunol 2006; 118: 957-958.
20. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, et al: EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007, in press.
21. Kowalski ML, Ptasinska A, Jedrzejczak M, Bienkiewicz B, Cieslak M, Grzegorc-zyk J, Pawliczak R, Dubuske L: Aspirin-triggered 15-HETE generation in pe-ripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPI Test). Allergy 2005; 60: 1139-1145.
22. Gamboa P, Sanz M, Caballero MR, Ur-rutia I, Antepara I, Esparza R, et al: The flow-cytometric determination of ba-sophil activation by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagno-sis of the NSAID hypersensitivity syn-drome. Clin Exp Allergy 2004; 34: 1448-1457.
23. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101: 834-846.
24. 2 me-tabolite) in plasma and urine of pa-tients with bronchial asthma and healthy controls after aspirin chal-lenge. J Allergy Clin Immunol 2003; 111: 743-749
25. Sanak M, Kielbasa B, Bochenek G, Szczeklik A: Exhaled eicosanoids fol-lowing oral aspirin challenge in asth-matic patients. Clin Exp Allergy 2004; 34: 1899-1904.
26. 4 excretion (hyperleuko-trienuria): involvement of chronic hy-perplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 2004; 113: 277-283.
27. Jinnai M, Sakagani T, Sekigawa T, Ka-kihara M, Nakajima T, Yoshud K, Goto S, Hasegawa T, Koshino T, Hasegawa Y, Inoue H, Suzuki N, Sano Y, Inoue I: Polymorphisms in the prostaglandin E 2 receptor subtype 2 confer susceptibility to aspirin-intolerant asthma: a candi-date gene approach. Hum Mol Genet 2004; 13: 3203-3217.
28. Ying S, Meng Q, Scadding G, Parikh A, Corrigan CJ, Lee TH: Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expres-sion on nasal mucosal inflammatory cells. J Allergy Clin Immunol 2006; 117: 312-318.
29. Contoli M, Message SD, Laza-Stanc V, Edwards MR, Wark PAB, Bartlett NW, Kebadze T, Mallia P, Stanciu LA, Parker HL, Slater L, Lewis-Antes A, Kon OM, Holgate ST, Davies DE, Kotenko SV, Papi A, Johnston SL: Role of deficient type III interferon-γ production in asthma exacerbations. Nat Med 2006;12:1023-1026.
30. Dahlen B, Nizankowska E, Szczeklik A, Zetterstrom O, Bochenek G, Kumlin M, et al: Benefits from adding the 5-lipox-ygenase inhibitor zileuton to conven-tional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157: 1187-1194.
31. Mastalerz L, Nizankowska E, Sanak M, Mejza F, Pierzchalska M, Bazan-Socha S, et al: Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002; 32: 949-955.
32. Park HE, Kim SH, Sampson A, Lee KW, Park CS: The HLA-DPB1*0301 marker might predict the requirement for leu-kotriene receptor antagonist in patients with aspirin-intolerant asthma. J Al-lergy Clin Immunol 2004; 114: 688-689.
33. Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A: Histo-logical spectrum of cutaneous reac-tions to aspirin in chronic idiopathic urticaria. J Cutan Pathol 2004; 31: 323-329.
34. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A: Hypersensitivity to aspi-rin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004; 113: 771-775.
35. Stevenson DD, Simon RA, Zuraw BL: Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs; in Adkinson NF, Yunginger JW, Busse WW, et al (eds): Middleton's Allergy Principles and Practise. St Louis, Mosby, 2003, pp 1695-1710.
36. Czernawiska-Mysik G, Szczeklik A: Idiosyncrasy to pyrazolone drugs. Al-lergy 1981; 36: 381-384.
37. Szczeklik A, Nizankowska E, Czer-niawska-Mysik G: Tolerance of azopro-pazone: allergic and pseudoallergic reactions and comparison with other NSAIDs; in Rainsford KD (ed): Azopro-pazone. Over Two Decades of Clinical Use. Dordrecht, Kluver Academic, 1989, pp 265-274.
38. Kowalski ML, Woszczek G, Bienkie-wicz B, Mis M: Association of pyrazo-lone drug hypersensitivity with HLA-DQ and DR antigens. Clin Exp Allergy 1998; 28: 1153-1158.